Recon: FDA rejects drugs from Amryt, Reata; Viatris settles EpiPen antitrust suit for $264M
ReconJoanne S. Eglovitch
Biologics/ biosimilars/ vaccinesBiotechnologyDiagnostics/IVDsEuropeGlobalMedical DevicesNorth AmericaPharmaceuticalsRegulatory Intelligence/Policy